Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S061000, C546S062000, C546S075000, C514S285000
Reexamination Certificate
active
10503796
ABSTRACT:
Mono-ester and asymmetrically substituted diesters of dihydrexidine, dinapsoline and A-86929 and substituted derivatives thereof are described. The novel ester/diester derivatives exhibit improved pharmacokinetic characteristics relative to their unesterified parent compounds and can be formulated into pharmaceutical compositions useful for the treatment of a wide variety of dopamine related disorders.
REFERENCES:
patent: 4282227 (1981-08-01), Brenner
patent: 4340600 (1982-07-01), Brenner et al.
patent: 5047536 (1991-09-01), Nichols
patent: 5420134 (1995-05-01), Nichols et al.
patent: 5597832 (1997-01-01), Michaelides et al.
patent: 6194423 (2001-02-01), Nichols et al.
patent: WO 92/04356 (1992-03-01), None
patent: WO 94/22858 (1994-10-01), None
patent: WO 96/02513 (1996-02-01), None
PCT International Search Report for PCT/US03/04592 completed by the U.S. Searching Authority on May 5, 2003.
C. Kaiser and T. Jain, “Dopamine Receptors: Functions, Subtypes and Emerging Concepts”, Medicinal Research Reviews, 5:145-229, 1985.
D. Sibley and F. Monsma, “Molecular Biology of Dopamine receptors”, in TIPS, vol. 13, pp. 61-69, 1992.
G.P. Reynolds, “Developments in the drug treatment of schizophrenia”, in TIPS, :116-121, 1992.
M. Del Zompo et al, “Dopamine agonists in the treatment of schizophrenia”, Progress in Brain Research, E:41-48, 1986 end.
M. Davidson, “Effects of the D-1 Agonist SKF-38393 Combined With Haloperidol in Schizophrenic Patients”, Arch Gen. Psychiatry, 42:190-191, 1990.
R.A. Wise and P.P. Rompre in “Brain Dopamine and Reward”, Annual Review of Psychology, 40:191-225, 1989.
D.R. Britton et al, “Evidence for Involvement of Both D1 and D2 Receptors in Maintaining Cocaine Self-Administration”, Pharmacology Biochemistry & Behavior, 89:911-915, 1991.
R. Muscat et al., “Antidepressant-like effects of dopamine agonists in an animal model of depression”, Biological Psychiatry, 31:937-946, 1992.
F. Levy, “The Dopamine Theory of Attention Deficit Hyperactivity Disorder (ADHD)”, in Australian and New Zealand Journal of Psychiatry, 2:277-283, 1991.
Talley at al., Clin. Res., 18:518, 1970.
H.E. Katerinopoulos and D.I. Schuster, “Structure-Activity Relationships for Dopamine Analogs A Review”, in Drugs Of The Future, vol. 12, pp. 223-253, 1987.
P.H. Anderson et al, European Journal of Pharmacology, 137:291-292, 1987.
W.K. Brewster al., “trans-1 0,11-dihydroxy-5,6,6a,7,8,1 2b-hexahydrobenzo[a]phenanthridine: A Highly Potent Selective Dopamine D1 Full Agonist”, in Journal of Medicinal Chemistry, D:1756-1784, 1990.
H. Y. Meltzer, “Novel Approaches to the Pharmacology of Schizophrenia”, Drug Development Research, 9:23-40, 1986.
Jenner, P., “The rationale for the use of dopamine agonists in Parkinson's disease” Neurology 45(3): S6-12 (1995).
Wolters, EC, et al., “Dopamine agonists in Parkinson's disease” Neurology 45(3): S28-S34 (1995).
Aldrich, MS, et al., “Dopamine-receptor autoradiography of human narcoleptic brain” Neurology 42(2):410-415 (1992).
Tintner R., and Jankovic J., “Assessment and Treatment of Parkinson's Disease” Clinical Geriatrics 09(01): 1070-1389 (2001).
Davis KL, et al., “Dopamine in schizophrenia: a review and reconceptualization” Am. J. Psychiatry 148:1474-1486 (1991).
Lynch, MR, “Schizophrenia and the D1receptor: focus on negative symptoms” Prog Neuro-psychopharmacol. Biol. Psychiatry 16(6):797-832 (1992).
Castner, SA, et al., “Reversal of Antipsychotic Induced Working Memory Deficits by Short-Term Dopamine D1Receptor Stimulation” Science 287(5460):2020-2022 (2000).
Floresco SB, and Phillips, AG, “Delay-dependent modulation of memory retrieval by infusion of a dopamine D1agonist into the rat medial prefrontal cortex” Behav. Neurosci. 115(4):934-939 (2001).
Hersi, Al, et al., “Dopamine D1receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats” Neuroscience 69(4):1067-1074 (1995).
George TP, et al. “The potential of dopamine agonists in drug addiction” Expert Opinion on Investigational Drugs 11(4):491-499 (2002).
Britton DR, et al., “Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration” Pharmacol. Biochem. Behav. 39(4):911-5 (1991).
Jackson DM, et al., “Dopamine D2agonist-induced behavioural depression is reversed by dopamine D1agonists” Journal of Neural Transmission 75(3):213-220 (1989).
Cook, EH Jr., et al., “Association of attention-deficit disorder and the dopamine transporter gene” Am. J. Hum. Genet. 56(4):993-8 (1995).
Pliszka, Steven R. et al., “Catecholamines in Attention-Deficit Hyperactivity Disorder: Current Perspectives” J. Am. Acad. Child Adolesc. Psychiatry 35(3):264-272 (1996).
Dijkstra Durk
Wikstrom Hakan
Aulakh Charanjit S.
Barnes & Thornburg LLP
DarPharma, Inc.
LandOfFree
Mono-ester and asymmetrically substatuted di-ester pro-drugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mono-ester and asymmetrically substatuted di-ester pro-drugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mono-ester and asymmetrically substatuted di-ester pro-drugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3791204